Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$1.95
-1.5%
$2.81
$1.75
$39.38
$14.73M5.3199,142 shs29,428 shs
Flora Growth Corp. stock logo
FLGC
Flora Growth
$0.64
+6.8%
$0.66
$0.42
$2.11
$13.43M1.97274,514 shs71,171 shs
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$3.94
$1.56
$21.96
$3.47M1.13617,505 shs243,634 shs
Rallybio Corporation stock logo
RLYB
Rallybio
$0.34
+4.7%
$0.33
$0.22
$1.54
$13.84M-1.17106,177 shs54,924 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.00%+5.41%-28.57%-31.25%-92.66%
Flora Growth Corp. stock logo
FLGC
Flora Growth
0.00%+4.10%+1.76%+29.33%-34.85%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00%0.00%0.00%-3.77%-77.75%
Rallybio Corporation stock logo
RLYB
Rallybio
0.00%+1.62%-0.35%-24.89%-73.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Flora Growth Corp. stock logo
FLGC
Flora Growth
3.0174 of 5 stars
3.35.00.00.02.70.80.6
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/AN/AN/AN/A
Rallybio Corporation stock logo
RLYB
Rallybio
2.1675 of 5 stars
3.03.00.00.00.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.00
N/AN/AN/A
Flora Growth Corp. stock logo
FLGC
Flora Growth
2.50
Moderate Buy$4.00529.92% Upside
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00
N/AN/AN/A
Rallybio Corporation stock logo
RLYB
Rallybio
2.00
Hold$10.002,858.58% Upside

Current Analyst Ratings Breakdown

Latest ONVO, RLYB, FLGC, and ERNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2025
Rallybio Corporation stock logo
RLYB
Rallybio
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/13/2025
Rallybio Corporation stock logo
RLYB
Rallybio
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/9/2025
Rallybio Corporation stock logo
RLYB
Rallybio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
4/8/2025
Rallybio Corporation stock logo
RLYB
Rallybio
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$580K24.74N/AN/A$0.50 per share3.90
Flora Growth Corp. stock logo
FLGC
Flora Growth
$59.51M0.24N/AN/A$0.31 per share2.05
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$122K0.00N/AN/A$0.02 per share0.00
Rallybio Corporation stock logo
RLYB
Rallybio
$640K21.98N/AN/A$1.49 per share0.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$44.54M-$8.31N/AN/A-7,652.75%N/A-285.71%8/11/2025 (Estimated)
Flora Growth Corp. stock logo
FLGC
Flora Growth
-$15.91M-$0.98N/AN/AN/A-24.85%-216.49%-45.56%8/11/2025 (Estimated)
Organovo Holdings, Inc. stock logo
ONVO
Organovo
-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%N/A
Rallybio Corporation stock logo
RLYB
Rallybio
-$57.78M-$1.09N/AN/AN/A-5,682.19%-72.31%-64.78%8/14/2025 (Estimated)

Latest ONVO, RLYB, FLGC, and ERNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Flora Growth Corp. stock logo
FLGC
Flora Growth
-$0.01-$0.04-$0.03-$0.04$14.79 million$11.79 million
5/8/2025Q1 2025
Rallybio Corporation stock logo
RLYB
Rallybio
-$0.21-$0.21N/A-$0.21N/A$0.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/A
Flora Growth Corp. stock logo
FLGC
Flora Growth
N/AN/AN/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/A
Rallybio Corporation stock logo
RLYB
Rallybio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A
0.21
0.21
Flora Growth Corp. stock logo
FLGC
Flora Growth
0.88
1.05
0.67
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/A
0.72
1.72
Rallybio Corporation stock logo
RLYB
Rallybio
N/A
14.68
14.68

Institutional Ownership

CompanyInstitutional Ownership
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
70.55%
Flora Growth Corp. stock logo
FLGC
Flora Growth
36.01%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
8.23%
Rallybio Corporation stock logo
RLYB
Rallybio
90.34%

Insider Ownership

CompanyInsider Ownership
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
1.50%
Flora Growth Corp. stock logo
FLGC
Flora Growth
12.56%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
3.72%
Rallybio Corporation stock logo
RLYB
Rallybio
8.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
107.36 million7.26 millionNo Data
Flora Growth Corp. stock logo
FLGC
Flora Growth
28022.57 million19.73 millionNot Optionable
Organovo Holdings, Inc. stock logo
ONVO
Organovo
201.70 million14.79 millionOptionable
Rallybio Corporation stock logo
RLYB
Rallybio
4041.61 million37.99 millionNot Optionable

Recent News About These Companies

Jones Trading Downgrades Rallybio (RLYB)
Rallybio downgraded to Hold from Buy at JonesResearch
Rallybio downgraded to In Line from Outperform at Evercore ISI
Rallybio (RLYB) was downgraded to a Hold Rating at H.C. Wainwright
Rallybio discontinues RLYB212 program
Rallybio sinks as it drops RLYB212 for prevention of FNAIT
Citizens JMP downgrades Rallybio on RLYB212 discontinuation
JMP Securities downgrades Rallybio (RLYB) to a Hold
Rallybio reports Q4 EPS (25c), consensus (30c)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ernexa Therapeutics stock logo

Ernexa Therapeutics NASDAQ:ERNA

$1.95 -0.03 (-1.52%)
Closing price 07/3/2025 01:36 PM Eastern
Extended Trading
$1.95 0.00 (0.00%)
As of 07/3/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Flora Growth stock logo

Flora Growth NASDAQ:FLGC

$0.64 +0.04 (+6.79%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$0.64 0.00 (0.00%)
As of 07/3/2025 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

Organovo stock logo

Organovo NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Rallybio stock logo

Rallybio NASDAQ:RLYB

$0.34 +0.02 (+4.68%)
Closing price 07/3/2025 02:50 PM Eastern
Extended Trading
$0.34 0.00 (0.00%)
As of 07/3/2025 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.